Hims & Hers Tries to Recover from Late Monday Losses

Aug 5, 2025 - 15:00
Hims & Hers Tries to Recover from Late Monday Losses

Shares of Hims & Hers Health (NYSE:HIMS) fell 9% in extended trading on Monday after the telehealth company reported second-quarter results that missed Wall Street’s expectations for revenue.

Earnings per share proved to be 17 cents adjusted vs. 15 cents expected

Revenue: $544.8 million vs. $552 million expected

Revenue at increased 73% in the second quarter from $315.6 million during the same period last year, according to a release. Hims & Hers reported a net income of $42.5 million, or 17 cents per share, compared to $13.3 million, or six cents per share, during the same period a year earlier.

For its third quarter, Hims & Hers said it expected to report revenue between $570 million and $590 million, while analysts were expecting $583 million. The company said its adjusted earnings before interest, taxes, depreciation and amortization, or EBITDA, for the quarter will be between the range of $60 million and $70 million. Analysts polled by StreetAccount were expecting $77.1 million.

Hims & Hers has faced controversy in recent months over its continued sale of compounded GLP-1s, which are cheaper, unapproved versions of the blockbuster diabetes and weight loss drugs. Compounded drugs can be mass-produced when brand-name treatments are in shortage, but the U.S. Food and Drug Administration announced in February that ongoing supply issues had been resolved.

HIMS shares poked up six cents to begin Tuesday at $63.41.